219 related articles for article (PubMed ID: 6176154)
1. Effect of human interferon on vesicular stomatitis virus released from bovine embryonic kidney cells.
Harrell SA; Maheshwari RK; Mohanty SB; Friedman RM
Am J Vet Res; 1982 Apr; 43(4):565-8. PubMed ID: 6176154
[TBL] [Abstract][Full Text] [Related]
2. Release of low infectivity vesicular stomatitis virus particles from tunicamycin-treated cells.
Maheshwari RK; Singh VK; Husain MM; Friedman RM; Mohanty SB
J Exp Pathol; 1985; 2(3):149-63. PubMed ID: 3023584
[TBL] [Abstract][Full Text] [Related]
3. Morphological and biochemical characterization of vesicular stomatitis virus with low infectivity released from interferon treated cells.
Maheshwari RK; Friedman RM
Uttar Pradesh State Dent J; 1980 Jul; 11(3):95-110. PubMed ID: 6159713
[No Abstract] [Full Text] [Related]
4. Interferon-treated cells release vesicular stomatitis virus particles lacking glycoprotein spikes: correlation with biochemical data.
Maheshwari RK; Demsey AE; Mohanty SB; Friedman RM
Proc Natl Acad Sci U S A; 1980 Apr; 77(4):2284-7. PubMed ID: 6154948
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of interferon action. Interferon alpha inhibits vesicular stomatitis virus primary transcript accumulation in P1/eIF-2 alpha protein kinase-deficient human fibroblast cells.
Zhang XT; Samuel CE
J Biol Regul Homeost Agents; 1987; 1(4):157-65. PubMed ID: 2845723
[TBL] [Abstract][Full Text] [Related]
6. Different antiviral activity and cell specificity of interferon preparations produced by mouse peritoneal cells at 37 degrees C and at 26 degrees C.
Cembrzyńska-Nowak M
Arch Immunol Ther Exp (Warsz); 1989; 37(5-6):499-502. PubMed ID: 2484831
[TBL] [Abstract][Full Text] [Related]
7. Quantification of the antiviral effect of interferon by immunoassay of vesicular stomatitis virus proteins.
Wallach D
J Gen Virol; 1983 Oct; 64 (Pt 10)():2221-7. PubMed ID: 6194250
[TBL] [Abstract][Full Text] [Related]
8. Interferon alters intracellular transport of vesicular stomatitis virus glycoprotein.
Singh VK; Maheshwari RK; Damewood GP; Stephensen CB; Oliver C; Friedman RM
J Biol Regul Homeost Agents; 1988; 2(2):53-62. PubMed ID: 2461053
[TBL] [Abstract][Full Text] [Related]
9. Endogenous interferon (IFN) in patients with acute hepatitis B.
Boron-Kaczmarska A; Zachoval R; Zachoval V; Deinhardt F
Acta Med Hung; 1990; 47(1-2):77-80. PubMed ID: 1704122
[TBL] [Abstract][Full Text] [Related]
10. VSV replication in neurons is inhibited by type I IFN at multiple stages of infection.
Trottier MD; Palian BM; Reiss CS
Virology; 2005 Mar; 333(2):215-25. PubMed ID: 15721356
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of vesicular stomatitis virus replication by epidermal growth factor in human epidermoid A-431 cells.
Korutla L; Kumar R
Biochem Biophys Res Commun; 1996 Mar; 220(3):670-4. PubMed ID: 8607823
[TBL] [Abstract][Full Text] [Related]
12. Production of vesicular stomatitis virus with low infectivity by interferon-treated cells.
Maheshwari RK; Friedman RM
J Gen Virol; 1979 Jul; 44(1):261-4. PubMed ID: 227998
[TBL] [Abstract][Full Text] [Related]
13. Interferon induces the production of membrane protein-deficient and infectivity-defective vesicular stomatitis virions through interference in the virion assembly process.
Jay FT; Dawood MR; Friedman RM
J Gen Virol; 1983 Mar; 64 Pt 3():707-12. PubMed ID: 6186764
[TBL] [Abstract][Full Text] [Related]
14. Low infectivity of vesicular stomatitis virus (VSV) particles released from interferon-treated cells is related to glycoprotein deficiency.
Maheshwari RK; Husain MM; Friedman RM
Biochem Biophys Res Commun; 1983 Nov; 117(1):161-8. PubMed ID: 6318745
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of interferon on glycoprotein and membrane protein of vesicular stomatitis virus released from murine and simian cells.
Drebot MA; Lee SH; Rozee KR
J Interferon Res; 1984; 4(2):167-72. PubMed ID: 6205101
[TBL] [Abstract][Full Text] [Related]
16. Effect of exogenous tumor necrosis factor alpha, interleukin 6 and interferons on vesicular stomatitis virus replication in human placenta and amniotic membrane organ cultures.
Paradowska E; Blach-Olszewska Z; Gierlińska M; Woytoń J
Arch Immunol Ther Exp (Warsz); 1996; 44(1):57-62. PubMed ID: 8874771
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
Fredericksen BL; Whitt MA
Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of VSV and EMCV replication by the interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain.
Carter CC; Gorbacheva VY; Vestal DJ
Arch Virol; 2005 Jun; 150(6):1213-20. PubMed ID: 15717119
[TBL] [Abstract][Full Text] [Related]
19. Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus.
Anderson SL; Carton JM; Lou J; Xing L; Rubin BY
Virology; 1999 Mar; 256(1):8-14. PubMed ID: 10087221
[TBL] [Abstract][Full Text] [Related]
20. Effect of interferon treatment on vesicular stomatitis virus (VSV): release of unusual particles with low infectivity.
Maheshwari RK; Friedman RM
Virology; 1980 Mar; 101(2):399-407. PubMed ID: 6244697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
